Isoquinolin‐1‐one Inhibitors of the MDM2–p53 Interaction

p53 has been at the centre of attention for drug design since the discovery of its growth‐suppressive and pro‐apoptotic activity. Herein we report the design and characterisation of a new class of isoquinolinone inhibitors of the MDM2–p53 interaction. Our identification of druglike and selective inhibitors of this protein–protein interaction included a straightforward in silico compound‐selection process, a recently reported NMR spectroscopic approach for studying the MDM2–p53 interaction, and selectivity screening assays using cells with the same genetic background. The selected inhibitors were all able to induce apoptosis and the expression of p53‐related genes, but only the isoquinolin‐1‐one‐based inhibitors stabilised p53. Our NMR experiments give a persuading explanation for these results, showing that isoquinolin‐1‐one derivates are able to dissociate the preformed MDM2–p53 complex in vitro, releasing a folded and soluble p53. The joint application of these methods provides a framework for the discovery of protein interaction inhibitors as a promising starting point for further drug design.

[1]  C. Renner,et al.  Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. , 2001, Biochemistry.

[2]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[3]  A. Levine,et al.  Functions of the MDM2 oncoprotein , 1999, Cellular and Molecular Life Sciences CMLS.

[4]  Mahavir Singh,et al.  Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy. , 2005, Journal of the American Chemical Society.

[5]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[6]  M. Oren,et al.  The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.

[7]  D. Lane,et al.  What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53? , 1993 .

[8]  M. Cushman,et al.  Condensation of imines with homophthalic anhydrides. A convergent synthesis of cis- and trans-13-methyltetrahydroprotoberberines. , 1977, The Journal of organic chemistry.

[9]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[10]  M. Schroeder,et al.  LIGSITEcsc: predicting ligand binding sites using the Connolly surface and degree of conservation , 2006, BMC Structural Biology.

[11]  P. Chène Inhibition of the p53-hdm2 Interaction with Low Molecular Weight Compounds , 2004, Cell cycle.

[12]  T. Holak,et al.  Molecular Basis for the Inhibition of p53 by Mdmx , 2007, Cell cycle.

[13]  O. Doebner Die Synthese der α‐Alkyl‐β‐naphtocinchoninsäuren, eine specifische Reaction auf Aldehyde, insbesondere zum Nachweis derselben in ätherischen Oelen , 1894 .

[14]  J. Yadav,et al.  Room temperature ionic liquids promoted three-component coupling reactions: a facile synthesis of cis-isoquinolonic acids , 2003 .

[15]  Sudhir Agrawal,et al.  Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[17]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[18]  R. Dayam,et al.  Patented small molecule inhibitors of p53–MDM2 interaction , 2006, Expert opinion on therapeutic patents.

[19]  S. Angelova,et al.  Synthesis of trans/cis 4-substituted 3-furyl-2-phenethyltetrahydroisoquinolin-1-ones: conformation of the trans-4-(pyrrolidinylcarbonyl) derivative , 2006 .

[20]  Nie-fang Yu,et al.  Lewis acid-induced reaction of homophthalic anhydride with imines: a convenient synthesis of trans-isoquinolonic acids , 1998 .

[21]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[22]  Robert P. Sheridan,et al.  Calculating Similarities between Biological Activities in the MDL Drug Data Report Database , 2004, J. Chem. Inf. Model..

[23]  G. Tortora,et al.  A novel MDM2 anti‐sense oligonucleotide has anti‐tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer , 2000, International journal of cancer.

[24]  Xueliang Fang,et al.  Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. , 2006, Journal of medicinal chemistry.

[25]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[26]  P. Chène Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.

[27]  J. Niland,et al.  The MDM2 gene amplification database. , 1998, Nucleic acids research.

[28]  M. P. Koleck,et al.  Total synthesis of (.+-.)-chelidonine , 1980 .

[29]  B. Wasylyk,et al.  p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53 , 1999, Oncogene.

[30]  O. Döbner 1) Ueber α-Alkylcinchoninsäuren und α-Alkylchinoline , 1887 .

[31]  T. Holak,et al.  An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments. , 2007, Journal of medicinal chemistry.

[32]  Michael Almstetter,et al.  Discovery of New Multi Component Reactions with Combinatorial Methods , 1999 .

[33]  Ramaswamy Nilakantan,et al.  Topological torsion: a new molecular descriptor for SAR applications. Comparison with other descriptors , 1987, J. Chem. Inf. Comput. Sci..

[34]  H. Tian,et al.  One‐Pot Synthesis of cis‐Isoquinolonic Acid Derivatives via Three‐Component Reaction of Homophthalic Anhydride with Aldehydes and Amines using Ytterbium(III) Triflate as Catalyst , 2005 .

[35]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[36]  G. Evan,et al.  Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. , 2006, Cancer cell.

[37]  T. Holak,et al.  NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro , 2005, Nature Medicine.

[38]  David P. Lane,et al.  Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo , 1997, Current Biology.

[39]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[40]  A. Levine,et al.  Mapping of the p53 and mdm-2 interaction domains. , 1993, Molecular and cellular biology.

[41]  O. Doebner Ueber α‐Alkylcinchoninsäuren , 1887 .

[42]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.